Mesoblast Limited

Interim Results From Mesoblast's Phase 2 Heart Failure Trial Shows 'Off-the-Shelf' Proprietary Adult Stem Cell Product Revascor(TM) Reduces Cardiac Events, Mortality, and Hospitalization

U.S. Government Grants Awarded for Further Development of Adult Stem Cell Products

Phase 3 Meeting Scheduled With US FDA Following Positive Results of Bone Marrow Regeneration Trial

FRAZER, Pennsylvania and MELBOURNE, Australia, January 10, 2011 - Cephalon, Inc.

MELBOURNE, Australia, November 8, 2010 - Regenerative medicine company, Mesoblast Limited (ASX: MSB; USADR: MBLTY), today announced that its United States associate company, Angioblast Systems, has been awarded US$1.2 million in grants under the United States Government's Qualifying Therapeutic Discovery Project (QTDP) program.

MORE..

Older News

MELBOURNE, Australia, July 12, 2010 - Australian regenerative medicine company, Mesoblast Limited (ASX: MSB; ADR: MBLTY), today announced that based on positive results from its bone marrow transplant clinical trial conducted at the University of Texas MD Anderson Cancer Center, a formal meeting has been scheduled with the United States Food and Drug Administration (FDA) to discuss a proposed Phase 3 clinical trial program.

MORE..